KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial.

Yan Zhao, Melinda Gooderham, Bin Yang, Jiyuan Wu, Liming Wu, Wei Jing Loo, Darryl Toth, Maxwell Sauder, Jingyi Li, Aijun Chen, Xiaohua Tao, Jianyun Lu, Zhiqiang Song, Jiande Han, Hongyi Li, Yijing Li, Lihong Xu, Jianzhong Zhang

JAMA Dermatol 161(7) 688-697

PMID40305055
PMCIDPMC12044538
DOI10.1001/jamadermatol.2025.0982
发表日期2025-04-30
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other。
摘要

摘要

IMPORTANCE: Ivarmacitinib, a selective oral Janus kinase 1 (JAK1) inhibitor, has demonstrated efficacy for treating adults with moderate to severe atopic dermatitis (AD) in a phase 2 trial. OBJECTIVE: To evaluate the efficacy and adverse events of ivarmacitinib in adolescents and adults with moderate to severe AD. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial included patients aged 12 to 75 years with moderate to severe AD. Patients were enrolled from 53 sites in Canada and China from April 2021 to April 2022. Data were analyzed from July 11 to September 27, 2023. INTERVENTIONS: Patients were randomized (1:1:1) to receive once-daily 4- or 8-mg ivarmacitinib or placebo for 16 weeks. MAIN OUTCOMES AND MEASURES: Co-primary end points were the proportions of patients achieving an Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline and an Eczema Area and Severity Index score improvement of 75% (EASI-75) at week 16. RESULTS: Of 336 randomized patients (mean [SD] age, 31.1 [15.4] years; 213 [63.4%] male; 286 [85.1%] Asian), 113 received 4-mg ivarmacitinib, 112 received 8-mg ivarmacitinib, and 111 received placebo. At week 16, significantly more patients in the 4-mg ivarmacitinib group (41 of 113 [36.3%]; 95% CI, 27.5%-45.9%; P < .001) and the 8-mg ivarmacitinib group (47 of 112 [42.0%]; 95% CI, 32.7%-51.7%; P < .001) achieved an IGA score of 0 or 1 with at least a 2-grade improvement compared to the placebo group (10 of 111 [9.0%]; 95% CI, 4.4%-15.9%). EASI-75 responses were also significantly higher in the ivarmacitinib groups: 61 patients (54.0%; 95% CI, 44.4%-63.4%; P < .001) in the 4-mg group, and 74 (66.1%; 95% CI, 56.5%-74.8%; P < .001) in 8-mg group compared to 24 patients (21.6%; 95% CI, 14.4%-30.4%) in the placebo group. Treatment-emergent adverse events were reported by 78 patients (69.0%) in the 4-mg group, 74 (66.1%) in the 8-mg group, and 72 (64.9%) in the placebo group. Serious treatment-emergent adverse events occurred in 3 patients (2.7%) in the 4-mg group, 2 (1.8%) in the 8-mg group, and 3 (2.7%) in the placebo group. CONCLUSIONS AND RELEVANCE: This phase 3 randomized clinical trial determined that once-daily ivarmacitinib demonstrated significant efficacy and a favorable risk-benefit profile for treating moderate to severe AD in adults and adolescents. These results support the potential of ivarmacitinib as a new therapeutic option. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04875169.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. CONSORT Flow Diagram AD indicates atopic dermatitis, and TEAE, treatment-emergent adverse event.
非 KM Figure
Figure 2Figure 2.. Co-primary End Points at Week 16 of Ivarmacitinib Treatment for Moderate to Severe Atopic Dermatitis in Adults and Adolescents A, An IGA response was achieved in 41 of 113 patients (36.3%) in the 4-mg ivarmacitinib group, 47 of 112 patients (42.0%) in the 8-mg group, and 10 of 111 patients (9.0%) in the placebo group. B, An EASI-75 response was achieved in 61 of 113 patients (54%) in the 4-mg group, 74 of 112 patients (66.1%) in the 8-mg group, and 24 of 111 patients (21.6%) in the placebo group. Conclusion of statistical significance was controlled for multiplicity only at week 16. Error bars represent 95% CIs. EASI-75 indicates Eczema Area and Severity Index (75% improvement or greater), and IGA, Investigator Global Assessment (clear [score 0] or almost clear [1] with ≥2-grade improvement). a P < .001 vs placebo.
非 KM Figure